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California, USA.Substance use complicates HIV care and preven-
tion. Primary care clinics are an ideal setting to
screen for and offer interventions for unhealthy
alcohol and drug use; however, few HIV clinics
routinely screen for substance use. We enrolled 208
clinic patients at an urban underserved HIV primary
care clinic. We screened the patients for substance use
with the Alcohol, Smoking, and Substance Involve-
ment Score Test and measured urine toxicology. Of
the 168 participants who completed screening, the
majority reported tobacco or nonprescribed sub-
stance use in the previous 3 months. More African
American participants reported low or no risk
amphetamine use compared to Hispanic, White, or
Other race participants (p , .001). Implementing
standard clinic practice for screening and assessing
substance use in HIV primary care clinics is needed.
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ical, social, and psychological harmful effects of sub-
stance use. In addition, studies have reported the
harms of alcohol, tobacco, and illicit substance use
in this population (Gonzalez, Barinas, &
O’Cleirigh, 2011). In the general population as well
as in PLWH, the consequences of unrecognized and
untreated substance use are clinically, socially, and
economically significant. The U.S. Public Health Ser-
vice has endorsed routine and universal alcohol and
tobacco screening in primary care (U.S. Preventive
Services Task Force, 2004); however, few HIV pri-
mary care clinics routinely assess patients for alcohol
or other substance use (Surah et al., 2013).
The effects of alcohol, tobacco, and illicit sub-
stance use take a greater combined toll on the health
and well-being of Americans than any other prevent-
able factor. Alcohol and tobacco use are significant
risk factors for cardiovascular disease and cancer,
which are the leading causes of death (O’Keefe,
Bhatti, Bajwa, DiNicolantonio, & Lavie, 2014). In a
national survey on substance use (alcohol and illicit
drugs) and health, more than 71% of U.S. adults re-
ported alcohol use in the previous year (Substance
Abuse and Mental Health Services Administration,
2014). In 2007, substance use contributed to more
than half of suicides and violent crimes in the United
States (Sacks et al., 2009). The economic costs of the
global burden of disease and health care utilization
that are attributable to alcohol use are immense
(Rehm et al., 2010).
Alcohol, tobacco, and illicit drug use can compli-
cate HIV health care and health outcomes by inter-
fering with medication access and adherence,
contributing to HIV pathogenesis, increasing trans-
mission risk behaviors, and destabilizing sources of
social and financial support. PLWH who use sub-
stances are less likely to be prescribed ART, and
those on ART have reduced ART adherence (Golin
et al., 2002; Volkow & Montaner, 2010). Studies
that have enrolled active substance users show
mixed results on HIV medication adherence.
Historically, studies with PLWH who reported illicit
drug use while on ART had poorer health outcomes
than those who did not use drugs (Arnsten et al.,
2007), while more current studies of PLWH who in-
jected drugs and were on HIV treatment showed sur-
vival rates that were similar when compared to peoplewho injected drugs with those who did not (Spiller,
Broz, Wejnert, Nerlander, & Paz-Bailey, 2015). In
addition to complicating treatment and HIV out-
comes, research has also shown an association be-
tween active substance use (alcohol and illicit
drugs) and high-risk HIV transmission behaviors,
including unprotected anal and vaginal intercourse
with uninfected partners (Kalichman et al., 2009).
Stimulant use by PLWH is also a critical factor in
HIV health outcomes. Cocaine use has been shown to
enhance viral replication and quiescent T-cell permis-
siveness to HIV infection, increasing the viral reser-
voir; cocaine is also an independent factor for
unsuppressed viral load and increased neurocognitive
disorders (Kim et al., 2015). Methamphetamine use
has been associated with primary drug resistance to
nonnucleoside reverse transcriptase inhibitors,
increased cognitive decline, inflammation in the
brain, and ischemic events (Cattie et al., 2014). Meth-
amphetamine use also doubles or triples the probabil-
ity of engaging in high-risk sexual behavior and
acquisition of sexually transmitted infections,
including HIV (Colfax & Shoptaw, 2005). HIV infec-
tion is more likely in women who use crack cocaine
than in women who don’t; suicide attempts for
PLWH are more prevalent in persons who use drugs
(Walter & Petry, 2015) and are related to poorer
emotional and cognitive quality-of-life measures.
Several studies have now demonstrated the relation-
ship between substance use and HIV acquisition
and increased morbidity and mortality for PLWH
(Kuo et al., 2014).
Screening for substance use and identifying those
with risky alcohol and drug use behaviors in primary
care settings allows for an integrated approach to
respond to harmful substance use. As with many
chronic diseases, screening and early detection can
serve as a form of preventive care (Saitz et al.,
2010), as well as to identify patients where further
clinical intervention may be warranted. A study of
alcohol and drug use screening is especially relevant
in HIV clinical settings, where substance use is
widespread (Mimiaga et al., 2015). HIV care pro-
viders have the opportunity to identify and intervene
with patients who otherwise would be unlikely to ac-
cess specialty treatment for substance use. Screening
and assessment for unhealthy substance use offers
clinicians the opportunity to identify harmful
Dawson-Rose et al. / Substance Use in an HIV Primary Care Safety Net Clinic 3substance use or disorders and provides the opportu-
nity to address such use. However, few studies have
explored screening for substance use as part of HIV
primary care. The goal of our study was to charac-
terize patterns and severity of substance use through
two different screening and assessment approaches
in a large, urban public HIV clinic providing
primary care to PLWH and to describe gender and
racial differences in alcohol, tobacco, and other sub-
stance use.MethodsDesign: Sample, Setting, and Data Collection
Patients (N5 208) were recruited and enrolled in a
parent Screening, Brief Intervention, and Referral to
Treatment (SBIRT) trial (Dawson Rose et al., 2015).
Potential subjects were recruited from a convenience
sample of patients receiving HIV primary care at the
University of California San Francisco Positive
Health Program (PHP) clinic at San Francisco Gen-
eral Hospital. The PHP clinic is one of the oldest
and largest HIV clinics in the United States,
providing primary medical care to more than 2,500
HIV-infected patients annually. All study protocols
were reviewed and approved by the University of
California San Francisco Institutional Review Board
and the clinical site.
Study eligibility included: 18 years of age or older,
confirmed HIV-infected serostatus, ability to provide
informed consent to be a research participant and to
be followed over a 6-month period, ability to speak
English or Spanish, and receiving HIV care at the
PHP clinic. We also asked study participants for writ-
ten consent to abstract biological measures from their
electronic health records. Study materials were pro-
vided in both English and Spanish.
Study participants completed a self-administered
survey upon enrollment to the study. They were asked
to submit a urine specimen for drug toxicology
screening, although this was not a requirement for
study participation. Study participants included in
our sub-analysis completed both screening measures.
Participants received $35 for completing each study
visit and an additional $10 for urine samples
provided.Measures
Demographics. Participants completed a demo-
graphic questionnaire that we have used in multiple
studies with PLWH. The questionnaire asked about
age, gender, race, income adequacy, education, and
year of HIV diagnosis (Tyer-Viola et al., 2014).
Substance use screening tools. We used two sub-
stance use screening measures in this analysis: the
Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST; World Health
Organization [WHO] ASSIST Working Group,
2002), which is a validated screening tool for un-
healthy use, and the Sure-Screen urine toxicology
test (MEDTOX Diagnostics Inc., Burlington, NC).
The ASSIST is a low-cost, self-report, eight-item
screening questionnaire developed for use in primary
care settings to screen for the presence of alcohol and
other substance use disorders (Humeniuk et al., 2008;
WHO ASSIST Working Group, 2002). ASSIST
collects information about lifetime nonmedical
substance use, previous 3-month substance use, fre-
quency of use, cravings, and problems related to sub-
stance use–including health, social, legal, or financial
problems; failing to do what was normally expected
because of drug use; having someone express
concern about a person’s drug use; trying and failing
to control, cut down, or stop using; risk of current or
future harm; level of dependence; and injection drug
use. The responses are summed to provide both a
continuous Specific Substance Involvement Score
(SSIS) and validated cut points for each substance
that translate to low-, moderate-, or high-risk use,
which indexes the risk for each substance assessed.
A moderate SSIS risk score indicates individuals
who should be offered a brief intervention or a
referral for substance use treatment. A high-risk score
indicates a need for more intensive treatment or atten-
tion to the substance being used at high-risk levels.
Urine specimens were collected and screened us-
ing the eight-panel Sure-Screen (MEDTOX
Scientific, 2015), a rapid qualitative immunoassay
screening test for detection of multiple drugs and
drug metabolites in human urine. The Medtox
11-panel Sure-Screen tests for 11 substances at
the following cut-off concentrations: amphetamine
(d-amphetamine) 300 ng/mL, barbiturates (butalbital)
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mL, cocaine (benzoylecgonine) 100 ng/mL, metham-
phetamine (d-methamphetamine) 1000 ng/mL, meth-
adone (methadone) 200 ng/mL, opiates (morphine)
100 ng/mL, oxycodone 100 ng/mL, phencyclidine
(phencyclidine) 25 ng/mL, propoxyphene (norpro-
poxyphene) 300 ng/mL, and cannabinoids (11-nor-
9-carboxy-€A9-THC) 40 ng/mL. We did not conduct
confirmatory testing of positive immunoassay results
with gas chromatography/mass spectrometry or liquid
chromatography/tandem mass spectrometry.
Clinical measures. CD41 T cell count and HIV
viral load (VL) measurements were extracted from
electronic medical records in the hospital database.
Using the date of the participants’ study visit, the
most recent CD41 T cell count and VL measures
in the electronic medical record were retrieved. The
clinical site where these data were collected
measured VL with the RealTime HIV-1 VL assay
(Abbott Molecular, Des Plaines, IL), which has a
lower limit of detection of 70 HIV RNA copies/mL
(Arredondo et al., 2012).
Data Analysis
Descriptive statistics, including frequencies, per-
centages, means, and standard deviations, were
performed to characterize the sample. Pearson’s chi-
squared and Fischer’s exact test analyses were used
to determine differences in risk stratification of SSIS
scores between male and female genders, and across
the four race/ethnicity categories (African American,
Hispanic or Latino/a, White/Anglo, and Other) and
substances detected via urine toxicology. All analyses
were conducted with STATA 14 (StataCorp LP, Col-
lege Station, TX). Urine toxicology screens provide
information that will tell if a substance is present in
the urine or not; however, urine tests cannot be used
for diagnosis of a substance use disorder.ResultsSample Characteristics
We enrolled 208 HIV primary care clinic patients
from an urban public clinic. The analysis presentedhere is based on the 168 participants who completed
both the ASSIST questionnaire and urine drug-
screening procedure. The participants were primarily
male (68.4%), and more than one third (40.5%) were
African American (Table 1). There were no signifi-
cant demographic differences between the entire
sample of 208 and the analytic sample of 168. The
average age was 45.66 years (SD 5 8.45), with an
average of 12.40 years living with HIV. Over half
of the participants (53.6%) had an undetectable
HIV viral load (#75 copies/mL).
Alcohol and Substance Use
More than two thirds of the study sample reported
using tobacco or other nonprescribed substances in
the previous 3 months. Sixty-four percent of our par-
ticipants (n 5 106) reported alcohol use for the same
time period. As described in the Methods section, we
determined SSIS for each substance reported and
stratified these scores into low (0-3), moderate (4-
26), and high risk (271) for all substances except
alcohol (low risk 5 0-10, moderate risk 5 11-26,
high risk 5 271), following the validated ASSIST
scoring guidelines. More than half of our partici-
pants’ SSIS scores indicated moderate risk for to-
bacco, (n 5 91, 54.2%) and cannabis (n 5 85,
50.6%; Table 2). The three drug classes with the
greatest number of participants exhibiting high-risk
scores were for tobacco (n 5 28, 16.7%), cocaine
(n 5 19, 11.3%), and amphetamine (n 5 17,
10.1%). The SSIS for alcohol use indicated that
almost one-third of study participants (n 5 48) re-
ported a moderate risk level for alcohol and 6.7%
(n 5 11) had a high-risk score for alcohol use.
When comparing the SSIS score for each substance
by gender and race, we observed differences in re-
ported substance use. Compared to females, males in
this sample reported greater levels of moderate-risk
cannabis use (p5 0.07) and significantly greater levels
of moderate risk amphetamine use (p, 0.001). There
were also significant differences for tobacco use, with
Hispanic or Latino/a participants reporting lower risk
use than White/Anglo, or Other race participants
(p5 .04). Finally, more African American participants
reported low- or no-risk amphetamine use as compared
to Hispanic or Latino/a, White/Anglo, or Other race
participants (p , .001).
Table 1. Baseline Demographic Characteristics (N5 168)
Variable n or M % or SD
Age (n 5 163) M 5 45.66 SD 5 8.45
Gender
Male 115 68.4
Female (including 10
transgender females)
53 31.6
Race
African American/Black 68 40.5
Hispanic/Latino 27 16.1
White/Anglo (non-Hispanic) 55 32.7
Other 18 10.7
Education
High school, GED, or less 105 62.5
More than high school 63 37.5
Employed
Yes 26 15.7
No 140 84.3
Income
Totally inadequate 38 22.6
Barely adequate 103 61.3
Enough 27 16.1
Health insurance
Yes 138 82.6
No 29 17.4
Years since HIV diagnosis
(n 5 154)
M 5 12.40 SD 5 7.02
Viral load , 75 copies/mL 90 53.6
CD41 T cell count cells/mm3
(n 5 152)
M 5 514.74 SD 5 321.86
Tobacco use previous 3 months (n 5 167)
Yes 110 67.1
No 54 32.9
Alcohol use previous 3 months (n 5 164)
Yes 106 64.2
No 59 35.8
Illicit substance use previous 3 months (n 5 167)
Yes 134 80.2
No 33 19.8
Note. M 5 mean; SD 5 standard deviation; GED 5 Graduate
Equivalency Diploma.
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imens that tested positive for cannabis (52.4%),
nearly one third (28.6%) tested positive for cocaine,
and almost a quarter (24.4%) tested positive for ben-
zodiazepines. Significant gender differences in urine
toxicology were also present (Table 3). Male gender
was significantly associated with positive urine toxi-
cology for amphetamine (20.0%, p , .001) and
methamphetamine (25.2, p , .001). Female gender
was significantly associated with positive urinetoxicology for cocaine (39.6%, p 5 .03), methadone
(30.2%, p, .001), and opiates (28.3%, p5 .04). Sig-
nificant racial differences were also observed in urine
toxicology. Those of Other race or ethnicity screened
positive for cannabis use more frequently (77.8%,
p 5 .02). Both Hispanic or Latino/a participants
and White/Anglo participants screened positive for
cocaine (18.5% and 16.4% respectively, p , .001)
less frequently. African American race or ethnicity
was associated with lower levels of positive urine
toxicology for both amphetamine (5.9%, p 5 .03)
and methamphetamine (7.5%, p 5 .01).DiscussionIn this study of patients in an HIV primary care
clinic-based urban population, we found high rates
of self-reported substance use, which were confirmed
by urine toxicology testing. The SSIS risk scores for
all substances, excepting inhalants and hallucino-
gens, demonstrated that moderate- and high-risk sub-
stance use was highly prevalent in this sample of
patients. Reported substance use in this HIV clinic
sample was higher than in other studies of both
HIV and non-HIV primary care patient samples for
most substances reported except for tobacco use. In
the United States, approximately 19% of the adult
population smokes cigarettes (Centers for Disease
& Prevention, 2012). When compared to the U.S.
general population, a number of studies have docu-
mented considerably higher rates of smoking in
PLWH (Lifson & Lando, 2012), which is of grave
concern given the now well-documented increased
mortality associated with smoking in PLWH due to
cardiovascular disease and non-AIDS-related cancers
(Helleberg et al., 2015; Rasmussen et al., 2015). For
other substances such as cannabis, our sample
exhibited levels of use similar to other primary care
settings (Saitz et al., 2014) where the ASSIST mea-
sure was used. However, in another study of an
HIV clinic-based sample, the reported use of
cannabis was 18% (Skalski et al., 2015), which was
considerably lower than what we found in our study.
When examining other substances reported by par-
ticipants in our study, we saw similarities compared
to other clinic samples of HIV-infected and unin-
fected patients, for example, with stimulant use
Table 2. Specific Substance Involvement Scores Stratified by Risk Level, Gender, and Race (N 5 168)
Substance Risk Level
Total
Sample
n (%)
Male
n 5 115
n (%)
Femalea
n 5 53
n (%) p-Value
African
American
n 5 68
n (%)
Hispanic/
Latino
n 5 27
n (%)
White/
Anglo
n 5 55
n (%)
Other
n 5 18
n (%) p-Value
Tobacco Low 49 (29.2) 36 (31.3) 13 (24.5) .66 22 (32.4) 13 (48.2) 12 (21.8) 2 (11.1) .04*
Moderate 91 (54.2) 60 (52.2) 31 (58.5) 39 (57.4) 10 (37.0) 32 (58.2) 10 (55.6)
High 28 (16.7) 19 (16.5) 9 (17.0) 7 (10.3) 4 (14.8) 11 (20.0) 6 (33.3)
Alcoholb Low 106 (64.2) 68 (59.7) 38 (74.5) .20* 43 (63.2) 17 (65.4) 36 (66.7) 10 (58.8) .65*
Moderate 48 (29.1) 37 (32.5) 11 (21.6) 22 (32.4) 8 (30.8) 14 (25.9) 4 (23.5)
High 11 (6.7) 9 (7.9) 2 (3.9) 3 (4.4) 1 (3.9) 4 (7.4) 3 (17.7)
Cannabis Low 70 (41.7) 41 (35.7) 29 (54.7) .07* 33 (48.5) 13 (48.2) 16 (29.1) 8 (44.4) .25*
Moderate 85 (50.6) 64 (55.7) 21 (39.6) 31 (45.6) 11 (40.7) 35 (63.6) 8 (44.4)
High 13 (7.7) 10 (8.7) 3 (5.7) 4 (5.9) 3 (11.1) 4 (7.3) 2 (11.1)
Cocaine Low 94 (56.0) 64 (55.7) 30 (56.6) 1.00* 32 (47.1) 20 (74.1) 31 (56.4) 11 (61.1) .32*
Moderate 55 (32.7) 38 (33.0) 17 (32.1) 28 (41.2) 5 (18.5) 16 (29.1) 6 (33.3)
High 19 (11.3) 13 (11.3) 6 (11.3) 8 (11.8) 2 (7.4) 8 (14.6) 1 (5.6)
Amphetamine Low 96 (57.1) 54 (47.0) 42 (79.3) .00* 53 (77.9) 13 (48.2) 23 (41.8) 7 (38.9) .00*
Moderate 55 (32.7) 45 (39.1) 10 (18.9) 14 (20.6) 11 (40.7) 22 (40.0) 8 (44.4)
High 17 (10.1) 16 (13.9) 1 (1.9) 1 (1.5) 3 (11.1) 10 (18.2) 3 (16.7)
Inhalants Low 148 (88.1) 99 (86.1) 49 (92.5) .61* 62 (91.2) 23 (85.2) 47 (85.5) 16 (88.9) .79*
Moderate 19 (11.3) 15 (13.0) 4 (7.6) 6 (8.8) 4 (14.8) 7 (12.7) 2 (11.1)
High 1 (0.6) 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 0 (0.0)
Sedatives Low 120 (71.4) 79 (68.7) 41 (77.4) .58* 54 (79.4) 17 (63.0) 36 (65.5) 13 (72.2) .23*
Moderate 44 (26.2) 33 (28.7) 11 (20.8) 14 (20.6) 8 (29.6) 17 (30.9) 5 (27.8)
High 4 (2.4) 3 (2.6) 1 (1.8) 0 (0.0) 2 (7.4) 2 (3.6) 0 (0.0)
Hallucinogens Low 152 (90.5) 102 (88.7) 50 (94.3) .57* 63 (92.7) 25 (92.6) 47 (85.5) 17 (94.4) .71*
Moderate 13 (7.7) 10 (8.7) 3 (5.7) 4 (5.9) 1 (3.7) 7 (12.7) 1 (5.6)
High 3 (1.8) 3 (2.6) 0 (0.0) 1 (1.5) 1 (3.7) 1 (1.8) 0 (0.0)
Opioids Low 128 (76.2) 90 (78.3) 38 (71.7) .37* 56 (82.4) 22 (81.5) 36 (65.5) 14 (77.8) .20*
Moderate 34 (20.2) 20 (17.4) 14 (26.4) 10 (14.7) 3 (11.1) 17 (30.9) 4 (22.2)
High 6 (3.6) 5 (4.4) 1 (1.9) 2 (2.9) 2 (7.4) 2 (3.6) 0 (0.0)
Note. *Indicates Fisher’s Exact test.
Bold values indicate statistical significance.
a. Including 10 transgender women.
b. SSIS scores for alcohol: low (0-10), moderate (11-26), high (27+); for all other substances: low (0-3), moderate (4-26), high (27+).
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et al., 2001; Cook et al., 2008). A large number of
participants in our sample reported moderate or
higher ASSIST scores for cocaine (44.0%) and
amphetamine-type stimulants (42.8%). There have
been a multitude of studies on stimulant use and
HIV, ranging from stimulants as a risk factor for
HIV transmission and as a method of managing
mental health symptoms and the experience of
discrimination, to the manner in which they impacted
adherence to ART; however, very few of these sam-
ples were drawn solely from clinic settings where
HIV care was delivered. In the studies that have
been conducted in HIV primary care settings, a range
of stimulant use has been reported. Skeer andcolleagues (2012) studied HIV-infected men who
have sex with men (MSM) in a large primary care
setting in Boston, Massachusetts, and reported that
21% of their sample used amphetamines. In an earlier
study (Bing et al., 2001) of a nationally representative
probability sample of PLWH, 40% of the subjects re-
ported using an illicit drug other than cannabis. In a
more recent study of the Women’s Interagency HIV
Study, investigators did not solely recruit samples
from HIV primary clinics; however, nearly one
third (28.6%) of the HIV-infected women in the sam-
ple reported crack cocaine use within the previous
3 months (Cook et al., 2008).
The participants in our study also reported a high
prevalence of moderate-severe SSIS for alcohol
Table 3. Substance Use by Urine Toxicology by Gender and Race (N 5 168)
Substance
Total
Sample
n (%)
Male
n 5 115
n (%)
Femalea
n 5 53
n (%) p-Value
African
American
n 5 68
n (%)
Hispanic/
Latino
n 5 27
n (%)
White/
Anglo
n 5 55
n (%)
Other
n 5 18
n (%) p-Value
Cannabis
Absent 80 (47.6) 52 (45.2) 28 (52.8) .36 41 (60.3) 11 (40.7) 24 (43.6) 4 (22.2) .02*
Present 88 (52.4) 63 (54.8) 25 (47.2) 27 (49.7) 16 (59.3) 31 (56.4) 14 (77.8)
Cocaine
Absent 120 (71.4) 88 (76.5) 32 (60.4) .03 38 (55.9) 22 (81.5) 46 (83.6) 14 (77.8) .00*
Present 48 (28.6) 27 (23.5) 21 (39.6) 30 (44.1) 5 (18.5) 9 (16.4) 4 (22.2)
Amphetamine
Absent 144 (85.7) 92 (80.0) 52 (98.1) .00* 64 (94.1) 20 (74.1) 44 (80.0) 16 (88.9) .03*
Present 24 (14.3) 23 (20.0) 1 (1.9) 4 (5.9) 7 (25.9) 11 (20.0) 2 (11.1)
Methamphetamine
Absent 137 (81.6) 86 (74.8) 51 (96.2) .00* 63 (92.6) 19 (70.4) 42 (76.4) 13 (72.2) .01*
Present 31 (18.4) 29 (25.2) 2 (3.8) 5 (7.5) 8 (29.6) 13 (23.6) 5 (27.8)
Benzodiazepines
Absent 127 (75.6) 90 (78.3) 37 (69.8) .24 53 (77.9) 21 (77.8) 38 (69.1) 15 (83.3) .60*
Present 41 (24.4) 25 (21.7) 16 (30.2) 15 (22.1) 6 (22.2) 17 (30.9) 3 (16.7)
Oxycodone
Absent 145 (86.3) 103 (89.6) 42 (79.2) .07 59 (86.8) 25 (92.6) 43 (78.2) 18 (100.0) .08*
Present 23 (13.7) 12 (10.4) 11 (20.8) 9 (13.2) 2 (7.4) 12 (21.8) 0 (0.0)
Methadone
Absent 139 (82.7) 102 (88.7) 37 (69.8) .00* 57 (83.8) 23 (85.2) 44 (80.0) 15 (83.3) .95*
Present 29 (17.3) 13 (11.3) 16 (30.2) 11 (16.2) 4 (14.8) 11 (20.0) 3 (16.7)
Opiates
Absent 136 (81.0) 98 (85.2) 38 (71.7) .04 54 (79.4) 23 (85.2) 44 (80.0) 15 (83.3) .96*
Present 32 (19.0) 17 (14.8) 16 (28.3) 14 (20.6) 4 (14.8) 11 (20.0) 3 (16.7)
Note. *Indicates Fisher’s exact test.
a. Including 10 transgender women.
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Drug Use and Health determined the national rate of
alcohol use disorders was 7% (Substance Abuse and
Mental Health Services Administration, 2014), while
studies conducted in general outpatient settings cite a
prevalence of unhealthy alcohol use ranging from 7%
to 20% (Saitz, 2005). The methods used in these
studies varied, however, and the prevalence of
alcohol use in general medical settings was much
lower than what we measured in our sample. Alcohol,
like other substance use, can complicate HIV care
and treatment outcomes, and continues to be a major
driver of HIV acquisition.
Substance use patterns can differ between women
and men. In the literature, many studies of HIV and
substance use conducted with MSM have focused
on alcohol or amphetamine use (Stahlman,
Javanbakht, Stirland, Guerry, & Gorbach, 2013),
while studies of HIV-infected women have beenmore focused on crack cocaine and heroin use
(Cook et al., 2008). In our study, we observed gender
differences in SSIS scores and in urine toxicology re-
sults. Males in our sample had a significantly higher
proportion of moderate or high-risk SSIS scores for
amphetamine (p , 0.001; Table 2), while women
had significantly higher levels of cocaine (p 50.03),
methadone (p , 0.001), and opiate (p 5 0.04) posi-
tive urines when compared to men (Table 3). This
differed from what we observed in the self-report
SSIS scores. While women were marginally more
likely than men to report moderate- or high-risk
cocaine use, this difference was not statistically sig-
nificant. Many studies in the HIV literature have
focused on men, MSM, or women and substance
use. To our knowledge, however, no studies analyzed
gender differences between men and women in an
HIV-infected sample. One more general study found
that women were more likely to have a substance use
8 JANAC Vol. -, No. -, -/- 2015disorder combined with other mental illness
compared to men; however, there were no gender dif-
ferences in the presence of a substance use disorder in
the absence of mental illness (Fries, Fedock, &
Kubiak, 2014).
Urine toxicology in our study looked different
from self-report responses using the ASSIST. Urine
drug screening is limited (with few exceptions) to
the detection of drug use within a few days before
the test and, as in most tests, false positives and false
negatives as well as technical problems can occur.
Although objective, the use of biomarkers is not
without limitation. The literature has indicated that,
in some persons who use drugs, self-report, when
compared to urine toxicology, verifies underreporting
of illicit substance use, although it is not known how
widespread this is. Also, some clinicians may
conduct urine screening as evidence of therapeutic
adherence and evidence of use or nonuse of illicit
drugs. In our sample, women had more methadone
and opiates in their urine when compared with men;
however, opiates and methadone are both commonly
prescribed in medical settings for both pain manage-
ment and opiate agonist therapy (Nosyk et al., 2014),
and we did not systematically ask participants if they
were being prescribed opiates. As reported by
Robinson-Papp, Elliott, Simpson, and Morgello
(2012), singular reliance on self-reports for imple-
mentation of substance use screening and brief
interventions has limitations. In addition, more stig-
matized drugs, such as cocaine, methamphetamine,
or heroin, may be underreported using self-report,
but could be documented with urine toxicology tests
(Decker et al., 2014). In our study, participants were
paid for urine testing, which might not happen in a
primary care setting, so motivation to provide a urine
sample may be different. While we are not advo-
cating urine screening as the initial step for screening
in a clinical setting, some clinicians may use it as a
tool to work with patients with a history of substance
use to validate their reported use and not as a test,
which could penalize the patient (Pellico, Gilliam,
Lee, & Kerns, 2014). Although substance use levels
differed by screening modality in our study, the evi-
dence clearly pointed to high levels of substance
use in this HIV clinic sample.
High amounts of reported substance use found in
our study and others highlights a critical problemthat HIV clinicians may be overlooking and that
could be addressed by universal substance use
screening. Based on the evidence of efficacy for
screening and offering a brief intervention for alcohol
and tobacco use, the U.S. Preventive Services Task
Force (2004) has recommended universal preventive
substance use screening in primary care for adoles-
cents and adults (Saitz et al., 2010). While screening
and brief intervention has shown promise for harmful
alcohol use and smoking (Pilowsky &Wu, 2012), the
efficacy of universal brief intervention for illicit drug
use and prescription drug misuse has not been univer-
sally recommended for primary care settings (Saitz
et al., 2014). However, because of the overwhelming
evidence that illicit drug use negatively impacts
health, research to determine the efficacy of
screening and brief intervention for drug use is
ongoing.
SBIRT has emerged as an important model for
identifying and addressing substance use problems
in health care settings (Madras et al., 2009). Brief
intervention approaches are typically delivered on
site, and individuals with more severe substance use
problems may also be offered referrals to specialized
treatment. Brief intervention for non-treatment-
seeking samples has strong support in the alcohol
literature (Cuijpers, Riper, & Lemmers, 2004;
Kaner et al., 2009), and some promising effects
have been observed with respect to other substance
use (Humeniuk et al., 2012; Ondersma, Svikis, &
Schuster, 2007). Substance use screening followed
by a brief intervention conducted by an individual
trained in motivational interviewing has been
extensively examined in adolescents and young
adults using drugs and alcohol. These studies have
revealed significant reductions in marijuana use
(Saitz et al., 2014); decreases in alcohol use, binge
drinking, and days of drug use (Winters & Leitten,
2007); lower alcohol, tobacco, and cannabis use
(McCambridge & Strang, 2005); and reductions in
illicit drug use (Peterson, Baer, Wells, Ginzler, &
Garrett, 2006).
To our knowledge, few studies of SBIRT have
been conducted in HIV settings. Cropsey and
colleagues (2013) conducted an SBIRT feasibility
and acceptability study in an HIV primary care
clinic to address the high rates of smoking by
PLWH; the findings of Cropsey’s study indicated
Dawson-Rose et al. / Substance Use in an HIV Primary Care Safety Net Clinic 9that SBIRT was feasible and acceptable to staff and
patients in the HIV primary care setting. Using
SBIRT as an approach for SBIRT was feasible and
acceptable for many participants in our study
(Dawson Rose et al., 2015). SBIRT has been imple-
mented in HIV settings in the state of Colorado and
results are forthcoming (Fischer, 2012). Given the
amount of substance use in PLWH and its impact
on HIV care engagement (O’Cleirigh, Magidson,
Skeer, Mayer, & Safren, 2014), screening and brief
intervention in HIV care settings could be a critical
component of the HIV care coordination. More
investigation is needed to determine how to best
implement substance use screening and brief inter-
vention within the workflows of primary care HIV
clinics.
Study Limitations
Our sample was recruited from the clinic waiting
room and thus represents patients that are engaged in
care and may not be representative of the entire
clinic. The most current patient demographic data
for the clinic indicated that most were male
(84.0%); the clinic was racially diverse, with
48.3% Caucasian, 24.4% African American, and
22.6% Hispanic or Latino/a. The demographic
report by the clinic also indicated that the HIVexpo-
sure category was primarily MSM (66.0%), but also
included heterosexual exposure (25.8%) and injec-
tion drug use (23.4%). Our study did not collect
data on HIV exposure category. Our efforts to over-
sample women and people of color were successful,
as demonstrated by our participants, who were 31%
women and 68% people of color, both populations
that are often underrepresented. In addition, the
high mean CD41 T cell count and high level of viral
suppression in our cohort, while typical of this clinic
and San Francisco on the whole, was atypical when
compared to Gardner’s cascade (Gardner, McLees,
Steiner, Del Rio, & Burman, 2011), and may have
indicated that, despite the prevalence of substance
use in our sample, the participants were able to con-
trol their use well enough to remain adherent to their
HIV regimens. It is also possible that patients were
receiving some type of substance use treatment
while enrolled in this study, although we did not
ask specifically about concurrent treatment. Thissuggests that the findings might not be widely gener-
alizable to other HIV clinic populations. Another
limitation of our study was that, although the current
science on screening for substance use recommends
using single-item screeners for clinical settings to
determine whether further assessment is needed,
we did not use a single-item screener to determine
the presence of binge drinking. However, we did
use a single-item question to determine the need to
administer the full ASSIST tool. As such, while
we can report on moderate- or high-risk alcohol
use, we cannot report our samples’ response to the
single-item screener, most specifically binge drink-
ing, which is an important indicator for further
assessment.ConclusionsAlthough there is ample evidence that PLWH
report unhealthy substance use at higher rates than
the U.S. general population and that this use impacts
medication adherence and HIV disease progression
and can result in increased risks for comorbid condi-
tions, HIV clinical settings are not systematically
screening for or addressing substance use in HIV pri-
mary care settings. Nurses are strategically placed to
promote health and encourage information exchange
with patients about the impact of substance use on
their health and well-being. Further, patients may
benefit from a clinical approach that includes a
team-based approach to screening and brief interven-
tion in HIV primary clinics. Normalizing substance
use screening, similar to routine blood pressure
assessment during clinic visits, could be a more inte-
grated component of holistic care. Efforts to educate
and train nurses in practice and as part of prelicensure
and primary care programs using the SBIRT model
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as a conflict of interest.Key Considerations PLWH are continuing to use substances that
place them at risk of poor health outcomes.
 Screening can be brief and still identify an indi-
vidual who uses substances.
 Screening results could offer the nurse and pa-
tient with HIV infection an opportunity to
discuss the risks of continued use.
 Screening begins a dialogue between nurses
and PLWH regarding risk reduction, health
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